Journal article
Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus
Y Hao, D Hansen, W Louthrenoo, YH Chen, J Cho, A Lateef, L Hamijoyo, SF Luo, YJJ Wu, S Navarra, L Zamora, Z Li, S Sockalingam, Y Katsumata, M Harigai, Z Zhang, M Chan, J Kikuchi, T Takeuchi, SC Bae Show all
Lupus Science and Medicine | BMJ PUBLISHING GROUP | Published : 2024
Abstract
Objectives The lupus low disease activity state (LLDAS) allows for certain clinical and/or serological activity of SLE, provided overall disease activity does not exceed predefined cut-offs. This study aimed to evaluate the outcomes of patients who achieved LLDAS with clinical activity, serological activity only or neither clinical nor serological activity. Methods Patients with SLE enrolled in a prospective multinational cohort from March 2013 to December 2020 who were in LLDAS at least once were included. Visits that fulfilled both LLDAS and Definition of Remission in SLE (DORIS) criteria were excluded. Results 2099 patients were included, with median follow-up of 3.5 (IQR 1.3-5.8) years. ..
View full abstractGrants
Awarded by National Research Foundation of Korea
Funding Acknowledgements
YH received a Melbourne Research Scholarship from The University of Melbourne. S- CB is supported in part by Basic Science Research Programme through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF- 2021R1A6A1A03038899). EM received an NHMRC Investigator Grant. MN holds an NHMRC Investigator Grant (GNT1176538). The APLC has received unrestricted project grants from AstraZeneca, Bristol- Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Research and Development, Merck Serono and UCB to support data collection and data and project management.